Derouazi, in 2015, created a unique class of cancer vaccines based on recombinant proteins, by combining recombinant protein with Z12, which provides a variety of CD8+ and CD4+ T-cell epitopes expressed by MHC class I and class II alleles. Here, CD4 is linked to cancer.